| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 544255000 | Four ring hetero atoms in the bicyclo ring system | 30 |
| 20080306262 | Novel Compound - A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof | 12-11-2008 |
| 20090043097 | Methods - A method for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof; from a compound of the formula: (IV); wherein L represents a leaving group. | 02-12-2009 |
| 20120264937 | NOVEL 3-SUBSTITUTED 7-IMINO-2-THIOXO-3, 7-DIHYDRO-2H-THIAZOLO [4,5-DI PYRIMIDIN-6-YL - AND PROCESS FOR PREPARATION THEREOF - The present invention relates to novel 3-substituted (7-imino-2-thioxo-3,7-dihydro-2H-thiazolo[4,5-d]pyrimidin-6-yl of formula 1 wherein R is selected from a group consisting of hydrogen, alkyl having carbon no up to 10, allyl, cycloalkyl, aromatic, substituted aromatics (halogen, OH, COOH, OCH | 10-18-2012 |
| 544256000 | Four ring nitrogens in the bicyclo ring system | 27 |
| 20090048444 | Process for Preparing Pyrido[2,3-d]pyrimidin-7-one and 3,4-Dihydropyrimido[4,5-d]pyrimidin-2(1H)-one Derivatives - The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) | 02-19-2009 |
| 20120123118 | Process For The Preparation Of Nitroorotic Acid - Subject of the present invention is a new improved process for the preparation of nitroorotic acid via nitration of orotic acid. | 05-17-2012 |
| 20130116432 | MODIFIED MACROMOLECULE - The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups. | 05-09-2013 |
| 20130303760 | New Process For The Preparation Of Nitroorotic Acid - Subject of the present invention is a new improved process for the preparation of nitroorotic acid via nitration of orotic acid. | 11-14-2013 |
| 544257000 | Pteridines (including hydrogenated) | 3 |
| 20080319192 | New dihydropteridione derivatives, process for their manufacture and their use as medicament - Disclosed are new dihydropteridinones of the formula (I) | 12-25-2008 |
| 20090270619 | METHOD FOR PRODUCING ALPHA FORM CRYSTALS OF SAPROPTERIN HYDROCHLORIDE - A method for selectively producing stable alpha form crystals of sapropterin hydrochloride is provided. In this method, the alpha form crystal of sapropterin hydrochloride is produced by dissolving sapropterin hydrochloride with hydrochloric acid at a concentration of not less than 4 mol/L at not less than 70 degrees C.; adding heated ethanol to the solution; and cooling the solution at a cooling rate of not faster than 3 degrees C./min to a temperature of 40 to 55 degrees C. to precipitate the crystals. | 10-29-2009 |
| 20140031546 | HYDRODEOXYGENATION CATALYST - A hydrodeoxygenation catalyst comprises a metal catalyst, an acid promoter, and a support. The metal catalyst is selected from platinum, palladium, ruthenium, rhenium rhodium, osmium, iridium, nickel, cobalt, molybdenum, copper, tin, or mixtures thereof. The support is a promoted-zirconium material including texture promoters and acid promoters. The hydrodeoxygenation catalyst may be used for hydrodeoxygenation (HDO) of sugar or sugar alcohol in an aqueous solution. In one embodiment the HDO catalyst may be used for HDO of fatty acids such as fatty acid methyl esters (FAME), triglycerols (in plant oil and animal fat), pyrolysis oil, or lignin. The hydrodeoxygenation catalyst for fatty acid process does not require the use of an acid promoter, it is optional. | 01-30-2014 |
| 544262000 | The other cyclo in the bicyclo ring system is five-membered | 20 |
| 20090099357 | AGENT FOR THE PREVENTION AND TREATMENT OF PROSTATIC HYPERPLASIA COMPRISING PYRAZOLOPYRIMIDINONE COMPOUND - The present invention relates to an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent in accordance with the present invention can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent of the invention causing few side effects can be efficiently used as a safe drug. | 04-16-2009 |
| 20090131662 | Compositions And Methods Pertaining To PNA Synthons And Oligomers Comprising A Universal Base - This invention is related to compositions and methods pertaining to PNA synthons, PNA oligomers and/or PNA/DNA Chimeras comprising a universal base. | 05-21-2009 |
| 20090131663 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES - A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed. | 05-21-2009 |
| 20100048896 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND - The present invention relates to a novel process for the industrial manufacture of polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide. | 02-25-2010 |
| 20100048897 | PROCESS FOR THE PREPARATION OF SILDENAFIL AND INTERMEDIATES THEREOF - The present invention discloses a process for preparing sildenafil and its intermediates having the structures outlined below: | 02-25-2010 |
| 20100210839 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES - The invention relates to the use of selective phosphodiesterase 9A (PDE9A) inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory. | 08-19-2010 |
| 20100298563 | PYRAZOLOPYRIMIDINE DERIVATIVES HAVING BIOLOGICAL ACTIVITY ON SEROTONIN RECEPTOR 5-HT2c - The present invention relates to a novel medicinal use of pyrazolopyrimidine compounds having superior effect as serotonin 5-HT | 11-25-2010 |
| 20110306762 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides an acid addition salt of Udenafil, a preparation method thereof and a pharmaceutical composition comprising the same. The acid addition salt of Udenafil in which Udenafil is bonded to an organic acid selected from the group consisting of oxalic acid, benzenesulfonic acid, camphorsulfonic acid, cinnamic acid, adipic acid and cyclamic acid, has excellent solubility in an aqueous medium, water stability and crystallinity, thereby being suitably applied for a pharmaceutical composition. | 12-15-2011 |
| 20120088912 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 04-12-2012 |
| 20130178623 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists. | 07-11-2013 |
| 20130225812 | BRUTON'S TYROSINIE KINASE ACTIVITY PROBE AND METHOD OF USING - Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use. | 08-29-2013 |
| 20140039186 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 02-06-2014 |
| 20140128603 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS - The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. | 05-08-2014 |
| 20140155604 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID - The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid. | 06-05-2014 |
| 20140336382 | TYROSINE KINASE INHIBITORS - The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 11-13-2014 |
| 20150031881 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF - This invention generally relates to pyrazolo pyrimidine derivatives useful as, inter alia, inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. More specifically, the invention relates to pyrazolo pyrimidine derivatives, including derivatives and analogs of SDR inhibitors, pharmaceutical compositions containing derivatives and analogs of SDR inhibitors, methods of making derivatives and analogs of SDR inhibitors and methods of use thereof. | 01-29-2015 |
| 20150133661 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 05-14-2015 |
| 20160038497 | Enhanced Treatment Regimens Using mTOR Inhibitors - The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability. | 02-11-2016 |
| 20160090389 | Phosphoinositide 3-Kinase Inhibitors - The present invention relates inter alia to a compound of formula (I) | 03-31-2016 |
| 20160176879 | Novel Hydroximic Acid Derivative and Medical Application Thereof | 06-23-2016 |
